for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ascendis Pharma A/S

ASND.OQ

Latest Trade

107.69USD

Change

4.33(+4.19%)

Volume

70,823

Today's Range

103.25

 - 

109.46

52 Week Range

53.29

 - 

133.61

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
103.36
Open
103.63
Volume
70,823
3M AVG Volume
5.67
Today's High
109.46
Today's Low
103.25
52 Week High
133.61
52 Week Low
53.29
Shares Out (MIL)
47.55
Market Cap (MIL)
4,850.39
Forward P/E
-19.26
Dividend (Yield %)
--

Next Event

Ascendis Pharma A/S at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Ascendis Pharma A/S Reports Q2 Loss Per Share Eur 1.25

Ascendis Pharma A/S Reports Q1 Loss Per Share Of EUR 1.24

Ascendis Pharma A/S Reports Full Year 2018 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Ascendis Pharma A/S

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism.

Industry

Biotechnology & Drugs

Contact Info

Tuborg Boulevard 5

http://www.ascendispharma.com/

Executive Leadership

Michael Wolff Jensen

Chairman of the Board, Senior Vice President, General Counsel

Jan Moeller Mikkelsen

President, Chief Executive Officer, Director

Scott T. Smith

Chief Financial Officer, Senior Vice President

Lotte Soenderbjerg

Senior Vice President, Chief Administrative Officer

Harald Rau

Senior Vice President, Chief Scientific Officer

Key Stats

1.40 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (EUR)

2016

-2.580

2017

-3.680

2018

-3.170

2019(E)

-4.849
Price To Earnings (TTM)
--
Price To Sales (TTM)
228.66
Price To Book (MRQ)
6.58
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
5.38
LT Debt To Equity (MRQ)
4.66
Return on Investment (TTM)
-34.37
Return on Equity (TTM)
-31.42

Latest News

MOVES-Credit Suisse bolsters life sciences banking team -memo

Credit Suisse Group AG has brought on three new senior investment bankers as it continues to build out its healthcare investment banking division, according to an internal memo reviewed by Reuters.

BRIEF-Ascendis Pharma Announces Dosing Of First Subjects In Phase 1 Trial Of Transcon CNP

* ASCENDIS PHARMA A/S ANNOUNCES DOSING OF FIRST SUBJECTS IN PHASE 1 TRIAL OF TRANSCON CNP

High-profile investors bet on stocks tied to millennials - Sohn Conference

Hedge fund managers at the high-profile 2018 Sohn Investment Conference in New York pitched stock ideas on Monday that they said should benefit from the growing clout of the millennial generation, ranging from online food ordering to homebuilders.

REFILE-UPDATE 1-High-profile investors bet on stocks tied to millennials -Sohn Conference

Hedge fund managers at the high-profile 2018 Sohn Investment Conference in New York pitched stock ideas on Monday, ranging from online food ordering to homebuilders, that should benefit from the growing clout of the millennial generation.

REFILE-High-profile investors bet on stocks tied to millennials -Sohn Conference

Hedge fund managers at the high-profile 2018 Sohn Investment Conference in New York pitched stock ideas on Monday ranging from online food ordering to homebuilders that should benefit from the growing clout of the millennial generation.

BRIEF-Ascendis Pharma Reports Full Year 2017 Financial Results

* ASCENDIS PHARMA A/S REPORTS FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Ascendis Pharma prices 3.9 mln American Depositary Shares At $57 Per ADS

* ASCENDIS PHARMA A/S ANNOUNCES PRICING OF PUBLIC OFFERING OF ADSS

BRIEF-Ascendis Pharma A/S Announces Proposed Public Offering Of ADSS

* ASCENDIS PHARMA A/S ANNOUNCES PROPOSED PUBLIC OFFERING OF ADSS

BRIEF-Ascendis Pharma Says Completed Target Enrollment In Phase 3 Trial Of Pediatric Growth Hormone Deficiency Treatment

* ASCENDIS PHARMA ANNOUNCES COMPLETION OF TARGET ENROLLMENT IN PHASE 3 TRIAL OF TRANSCON GROWTH HORMONE FOR PEDIATRIC GROWTH HORMONE DEFICIENCY

BRIEF-Ascendis Pharma Initiates Submissions In Australia To Enter Study With Transcon CNP

* ASCENDIS PHARMA SAYS ON DEC 20, INITIATED REGULATORY SUBMISSIONS IN AUSTRALIA TO ENTER INTO FIRST HUMAN CLINICAL STUDY WITH TRANSCON CNP - SEC FILING Source text : (http://bit.ly/2BTTLso) Further company coverage:

BRIEF-Ascendis Pharma A/S Q3 loss per share EUR 1.04

* Ascendis Pharma A/S reports third quarter 2017 financial results

BRIEF-Ascendis Pharma A/S prices public offering of 3.8 mln shares at $35.50 per ADS

* Ascendis Pharma A/S announces pricing of public offering of ADSs

BRIEF-Ascendis Pharma A/S announces proposed public offering of ADSs

* Ascendis Pharma A/S announces proposed public offering of ADSs

BRIEF-Ascendis Pharma A/S reports dosing of subjects in phase 1 trial of transcon pth

* Ascendis Pharma A/S announces dosing of subjects in phase 1 trial of Transcon pth

BRIEF-Ascendis Pharma Q2 loss per share EUR 0.94

* Ascendis Pharma A/S reports second quarter 2017 financial results

BRIEF-Ascendis Pharma says initiated regulatory submissions in Australia for entry into human clinical study with transcon parathyroid hormone

* Ascendis Pharma - initiated regulatory submissions in australia to enable co's entry into its first human clinical study with transcon parathyroid hormone Source text for Eikon: Further company coverage:

BRIEF-Ascendis Pharma A/S Q1 loss per share eur 0.78

* Ascendis pharma a/s reports first quarter 2017 financial results

BRIEF-Ascendis Pharma files to say may offer, sell up to $400 million ordinary shares from time to time in one or more offerings

* Ascendis Pharma A/S - files to say may offer, sell up to $400 million in aggregate of our ordinary shares (or adss representing such shares) from time to time in one or more offerings Source text: (http://bit.ly/2nDinPi) Further company coverage:

BRIEF-Ascendis Pharma A/S reports full year 2016 financial results

* Ascendis Pharma A/S reports full year 2016 financial results Source text for Eikon: Further company coverage:

BRIEF-Ascendis Pharma reports publication of comprehensive results from phase 2 trial of transcon growth hormone

* Ascendis Pharma A/S announces publication of comprehensive results from randomized, active-controlled phase 2 trial of once-weekly transcon growth hormone in pediatric patients Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up